Ground-breaking work creates novel oil-in-water nanoemulsions
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.
Particle Technology is an important discipline that underpins many industrial sectors, including biomedical applications, latex paints and coatings, engine oil additives, viscosity modifiers and emulsion stabilisation. Steve Armes, Professor of Polymer and Colloid Chemistry at the University of Sheffield, is one of the UK's leading experts in particle science and technology, with more than 30 years of research experience in this field. In particular, he designs a wide range of microscopic polymer particles on the nanoscale.
Professor Steve Armes said: "It is well known that oil and water do not mix. Similarly, the incorporation of oil droplets within inorganic crystals is highly counter-intuitive because there is a large difference in surface energy for these two components. Our new occlusion protocol, developed using the high-pressure LV-1 microfluidizer, has enabled either oil-soluble dyes or oil-dispersible hydrophobic nanoparticles to be incorporated for the first time within host crystals. This exciting new innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives for various commercial applications. In view of this, we have filed a preliminary patent application to protect the IP associated with our work.
Professor Ames added: “We are indebted to the excellent technical support provided by Analytik, which has enabled us to fully exploit the high-pressure LV-1 Microfluidizer for the production of well-defined nanoemulsions. We will be seeking their support and advice in the future as we seek to extend our studies to include water-in-oil nanoemulsions.”
The LV1 Microfluidizer is a high shear homogeniser which brings outstanding processing capabilities to samples as small as 1 mL. The LV1 has been designed to achieve operating pressures up to 30,000 psi for samples ranging from 1-6 mL. Using proprietary fixed-geometry interaction chamber technology, the LV1 is capable of processing a wide variety of fluids such as oil-in-water emulsions, solids-in-liquid suspensions, and cells, including the most difficult yeasts and plant cells, in as few as 1-2 passes. What's more, the process is repeatable and is guaranteed to scale up to pilot and/or production volumes.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance